• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Sintilimab plus anlotinib showed promising clinical and safety response to treat advanced cervical cancer

byJamie ParkandSamuel Chan
February 28, 2022
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The overall response rate was 54.8% in the intention-to-treat group while it was 59.0% in the efficacy-evaluable group.

2. Common treatment-related adverse events in patients receiving sintilimab plus anlotinib were hypothyroidism, elevated aspartate aminotransferase levels and hypertension.

Evidence Rating Level: 2 (Good)

Study Rundown: Cervical cancer is known as the 4th leading cause of cancer related deaths worldwide. Currently, the standard of care for recurrent or metastatic cervical cancer is platinum-based chemotherapy plus antiangiogenic therapy. However, there is scarce knowledge on the treatment for patients who are refractory or intolerant to the first line therapy. Sintilimab (selective anti-PD-L1 monoclonal) and anlotinib (multikinase inhibitor) as a combination therapy have been studied in other tumour types such as advanced non-small cell lung cancer. Therefore, this study aimed to explore the efficacy and safety of sintilimab plus anlotinib as second line or later treatment for PD-L1–positive (Combined Positive Score [CPS] ³1) recurrent or metastatic cervical cancer. CPS is a PD-L1 scoring method for multiple tumour types, including advanced cervical cancer. In the intention-to-treat group, 54.8% of the patients achieved investigator-confirmed complete response (CR) or partial response (PR). In the efficacy-evaluable group, the ORR was 59.0%. Hypothyroidism, elevated aspartate aminotransferase levels and hypertension were common treatment-related adverse events that were reported. 7 patients experienced grade 3 and above treatment-related adverse events and there were no treatment-related deaths. The main limitation of the analyses included enrollment of a limited number of patients and the inability to compare its efficacy with currently available treatments. Overall, this study demonstrated that sintilimab plus anlotinib could be a potential treatment for advanced cervical cancer. However, further investigation is required to examine the long-term efficacy and safety profile of the treatments.

Click to read the study in The Journal of Clinical Oncology

Relevant Reading: Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

In-Depth [prospective cohort]: This was an open-label, single-arm, phase II study. Patients were enrolled if they had previously received at least one type of systemic treatment or were intolerable to chemotherapy. A total of 42 patients were enrolled to receive the study treatment. 3 patients discontinued treatment [adverse events (n=2), withdrawal (n=1)] and therefore, 39 patients were included as part of the efficacy-evaluable population. The median follow-up period was 10.9 months (range: 0.03-19.2) and the median treatment duration was 7.0 months (range: 0.03-19.2). The overall response rate (ORR) for the intention-to-treat population was 54.8% (95% confidence interval [CI]: 38.7 to 70.2). In the efficacy-evaluable patient groups, the ORR was 59.0% (95% CI: 82.7-99.4). Common treatment-related adverse events of any grade included hypothyroidism (33%), elevated aspartate aminotransferase levels (21%) and hypertension (19%). Seven patients experienced grade 3 and above treatment-related adverse events. These included 3 cases of fistula, and one case of each of the following treatment-related adverse events: hypertension, diarrhea, fatigue, immune pneumonitis, immune myocarditis.

RELATED REPORTS

Pembrolizumab improves survival outcomes in cervical cancer patients

Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival

Bastilimab plus zalifrelimab showed promising clinical and safety response for the treatment of refractory cervical cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cervical cancermetastatic cervical cancerPD-L1
Previous Post

LentiGlobin efficacious for sickle cell disease hemolysis and vaso-occlusion

Next Post

Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma

RelatedReports

Cervical cancer screening practices less cost-effective than suggested guidelines
Obstetrics

Pembrolizumab improves survival outcomes in cervical cancer patients

February 15, 2022
Patient Basics: Cervical Cancer
Oncology

Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival

February 14, 2022
Cervical cancer screening practices less cost-effective than suggested guidelines
Oncology

Bastilimab plus zalifrelimab showed promising clinical and safety response for the treatment of refractory cervical cancer

January 10, 2022
#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

October 28, 2021
Next Post
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma

Family planning providers use long acting contraception more than general population

Immediate postpartum intrauterine device insertion associated with increased risk of device expulsion: the APEX-IUD study

Social media effective adjunct for contraception education

Patients discharged from inpatient psychiatric care may benefit from a text support program

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
  • Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer
  • Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.